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Abstract  More  than  90%  of  the  population  is  infected  by  Epstein-Barr  virus  (EBV),  which  has
sophisticatedly  evolved  to  survive  silently  in  B  cells  for  the  life  of  infected  individuals.  However,
if the  virus-host  balance  is  disturbed,  latent  EBV  infection  could  be  associated  with  several  lym-
phomas. The  age  at  primary  infection  varies  substantially  worldwide,  and  exposure  to  EBV  is
likely to  be  due  to  socioeconomic  factors.  In  Argentina,  EBV  infection  is  mostly  subclinical  and
90% of  patients  are  seropositive  by  the  age  of  3  years;  therefore,  its  epidemiological  charac-
teristics  resemble  those  of  an  underdeveloped  or  developing  population.  EBV-positive  Hodgkin
lymphoma  (HL)  in  young  adults  from  developed  populations  has  been  attributed  to  delayed
primary EBV  infection  as  suggested  by  the  association  with  recent  mononucleosis  development.
EBV-associated  Burkitt  lymphoma  and  Hodgkin  lymphoma  in  children  from  Argentina  display  fre-
quencies similar  to  those  observed  in  developed  countries,  whereas  EBV  presence  in  pediatric
diffuse large  B-cell  lymphoma  is  slightly  increased  compared  to  those  populations.  However,
EBV presence  is  statistically  associated  particularly  with  patients  <  10  years  of  age  in  all  three
entities. Therefore,  a  relationship  between  low  age  of  EBV  seroconversion  and  B-cell  lymphoma
development  risk  could  be  suggested  in  children  from  Argentina.
© 2015  Hospital  Infantil  de  México  Federico  Gómez.  Published  by  Masson  Doyma  México  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
PALABRAS  CLAVE Epidemiología  de  linfomas  pediátricos  asociados  con  el  virus  de  Epstein-Barr
Virus  de  Epstein-Barr; en  Argentina
 la  población  se  encuentra  infectada  con  el  virus  de  Epstein-Barr
 soﬁsticadamente  para  sobrevivir  de  por  vida  de  manera  silenciosaLinfoma  de  Hodgkin;
Linfoma  de  Burkitt;
Linfoma  difuso  de
Resumen  Más  del  90%  de
(VEB), que  ha  evolucionadocélulas  B;
Linfoma  pediátrico
en las  células  B  de  individuos  infectados.  Sin  embargo,  si  el  balance  entre  el  virus  y  el  huésped
se altera,  la  infección  latente  por  VEB  se  podría  asociar  con  linfomas  severos.  La  edad  de  la
∗ Corresponding author.
E-mail address: paola chabay@yahoo.com.ar (P. Chabay).
http://dx.doi.org/10.1016/j.bmhimx.2015.12.002
1665-1146/© 2015 Hospital Infantil de México Federico Gómez. Published by Masson Doyma México S.A. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
48  P.  Chabay,  M.V.  Preciado
infección  primaria  varía  sustancialmente  a  escala  global,  y  la  exposición  al  VEB  al  parecer  se
relaciona con  factores  socioeconómicos.  En  Argentina,  la  infección  por  VEB  es  mayormente
subclínica,  y  el  90%  de  los  pacientes  son  seropositivos  a  la  edad  de  3  an˜os.  Por  lo  tanto,  las  car-
acterísticas  epidemiológicas  se  asemejan  a  aquellas  de  una  población  subdesarrollada  o  en  vías
de desarrollo.  El  linfoma  de  Hodgkin  (LH)  positivo  para  VEB  en  adultos  jóvenes  se  ha  atribuido
a una  infección  por  VEB  tardía  en  economías  desarrolladas,  como  lo  sugiere  la  asociación  con  el
desarrollo de  mononucleosis.  En  Argentina,  el  linfoma  de  Burkitt  y  el  linfoma  de  Hodgkin  asoci-
ados con  VEB  en  nin˜os  presentan  frecuencias  similares  a  las  observadas  en  países  desarrollados,
mientras que  la  presencia  de  VEB  en  el  linfoma  difuso  de  células  B  pediátrico  se  encuentra
con un  ligero  aumento  comparado  con  estas  poblaciones.  Sin  embargo,  la  presencia  de  VEB
en los  tres  padecimientos  se  asocia  estadísticamente,  en  particular,  con  pacientes  menores  de
10 an˜os.  Por  ello,  se  podría  sugerir  una  la  relación  entre  la  menor  edad  de  seroconversión  y  el
riesgo de  desarrollo  de  linfoma  de  células  B  en  nin˜os  de  Argentina.
© 2015  Hospital  Infantil  de  México  Federico  Gómez.  Publicado  por  Masson  Doyma  México
S.A. Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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c. Introduction
pstein--Barr  virus  (EBV)  is  a  ubiquitous  double-stranded  DNA
irus  that  belongs  to  the  Herpesviridae  family  and  Gamma-
erpesvirinae  subfamily.  EBV  is  characterized  by  a  tropism
or  B-lymphocytes  displaying  latent  infection  in  the  host  and
he  capacity  for  transforming  B-lymphocytes.  More  than  90%
f  the  population  worldwide  carries  the  virus,1 which  has
ophisticatedly  evolved  to  survive  in  B  cells  for  the  life  of
nfected  individuals.  The  result  is  a  ﬁnely  balanced  relation-
hip  that  allows  the  virus  to  be  acquired  silently  early  in  life
nd  carried  thereafter  as  a  lifelong  asymptomatic  infection
n  the  B  lymphoid  system.  However,  the  virus-host  balance
an  be  disturbed  in  various  ways,  and  one  of  a  range  of  virus-
ssociated  diseases  may  then  ensue.2 Latent  EBV  infection  is
inked  to  many  human  malignancies.  In  immunocompetent
ersons,  EBV  is  associated  with  ∼20%  of  Burkitt  lymphoma
BL)  in  the  developed  world,  almost  all  African  BL,  50%  of
odgkin  lymphoma  (HL),  10%  gastric  carcinomas,  almost  all
ndemic  nasopharyngeal  carcinoma  (NPC),  certain  fractions
f  diffuse  large  B-cell  lymphoma  and  T-cell  lymphoma.  In  the
bsence  of  normal  T-cell  immune  responses,  EBV-infected
-lymphocyte  proliferations  can  cause  lymphoproliferative
isease  (LPD),  similar  to  post-transplant  LPD.  The  persis-
ence  of  EBV  genomes  in  cells  of  these  malignancies,  even
n  subjects  with  otherwise  normal  immune  response,  is  con-
istent  with  the  notion  that  EBV  genomes  are  important  for
alignant  cell  growth.3
The  age  at  primary  infection  varies  substantially  world-
ide,  and  exposure  to  EBV  is  likely  to  be  due  to
ocioeconomic  factors.  Young  children  most  likely  acquire
rimary  EBV  infection  due  to  close  contact  that  involves
xchange  of  oral  secretions  via  shared  items  such  as  toys,
ottles,  and  utensils.  Before  the  age  of  10  years,  pri-
ary  infection  is  usually  asymptomatic.  In  adolescents  and
oung  adults,  however,  primary  EBV  infection  frequently
resents  as  infectious  mononucleosis  (IM).  Seroprevalence
f  EBV  varies  widely  by  geographic  location.  Data  indicate
hat  primary  EBV  infection  occurs  at  a  younger  age  among
ersons  from  lower  vs.  higher  socioeconomic  backgrounds,
hich  has  been  attributed  to  crowded  living  conditions.4
 delay  in  acquiring  a  primary  EBV  infection  at  an  older
w
p
m
oge  in  childhood  or  adolescence,  which  usually  occurs  in
ore  developed  countries,  can  manifest  itself  as  infec-
ious  mononucleosis,  occurring  in  ∼25--75%  of  EBV-infected
ersons.5 The  severity  of  primary  EBV  infection  in  adults
ncreases  with  age,  and  patients  >  40  years  of  age  are  espe-
ially  prone  to  serious  illness.  EBV  infections  in  children
 10  years are  often  overlooked,  either  because  they  are
ntirely  asymptomatic  or  because  they  do  not  present  with
 typical  IM  syndrome.4
There  is  a  hypothesis  that  proposes  that  the  clini-
al  presentation  variability  related  to  the  age  of  EBV
rimary  infection  is  linked  to  the  different  magnitude
f  the  viral  dose  received  by  a  child  or  a  young
dult  through  salivary  contact.6 Another  possibility  is
hat  IM  in  adolescents  may  reﬂect  the  global  CD8+
-cell  lymphocytosis,  with  a  great  proportion  of  activated
BV-speciﬁc  CD8+  T-cells.7 In  contrast,  it  was  recently
escribed  in  children  from  Africa  that  asymptomatic  EBV
nfection  elicits  a  virus-speciﬁc  CD8+  T-cell  response  that
an  control  the  infection,  without  CD8+  T-cells  over-
xpansion.8 Moreover,  it  was  suggested  that  preexisting  NK
ell  populations  in  children  may  provide  an  explanation  for
hy  IM  occurs  more  frequently  in  adolescents  and  adults
han  in  children.9 In  Argentina,  EBV  infection  is  mostly  sub-
linical  and  90%  of  patients  are  seropositive  by  the  age  of  3
ears;  therefore,  its  epidemiological  characteristics  resem-
le  those  of  an  underdeveloped  or  developing  population.10
. EBV infection in relation to lymphoma
evelopment
s  previously  mentioned,  EBV  is  among  the  infectious
gents  whose  clinical  manifestations  vary  according  to  age
t  primary  infection.  Moreover,  its  epidemiological  behav-
or  is  similar  to  that  of  HL.  The  relatively  few  cases  of
BV-positive  HL  in  younger  adults  may  be  attributed  to
elayed  primary  EBV  infection  as  suggested  by  the  asso-
iation  with  mononucleosis.11 In  fact,  IM  was  associated
ith  an  increased  risk  of  EBV-positive  HL,  along  with  the
articularly  pronounced  risk  in  younger  adults.  Further-
ore,  IM-associated  lymphomas  occurred  with  a  median
f  2.9  years  after  infection  in  patients  from  a  developed
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population.  Although  the  idea  that  EBV  is  merely  an  eti-
ologically  innocent  passenger  in  the  neoplastic  HL  cells
cannot  easily  be  dismissed,  it  remains  more  likely  that  the
observed  association  indeed  reﬂects  causality,12 at  least  in
cases  with  recent  IM  development.  In  contrast,  no  associa-
tions  between  EBV  serology  status,  elevated  antibody  titers
against  EBNA-1,  EBNA-2,  VCA,  or  EA,  and  risk  of  non-Hodgkin
lymphoma  (NHL)  overall  was  demonstrated  in  immunocom-
petent  individuals,  with  the  possible  exception  of  chronic
lymphocytic  leukemia  (CLL).  Therefore,  it  was  proposed  that
the  biological  mechanism  for  the  causal  role  of  EBV  in  the
pathogenesis  of  NHL  would  predominantly  involve  immune
system  deregulation.13
The  temporal  risk  variation  in  HL  after  IM  suggests  that
the  predilection  for  the  younger  adult  age  group  may  simply
result  from  the  combination  of  age  and  time  since  IM  rather
than  from  other  mechanisms  particular  to  HL  in  younger
adults.14 It  is  therefore  tempting  to  speculate  that  a sim-
ilar  association  may  exist  between  primary  EBV  infection
and  HL  risk  at  any  age,  e.g.,  in  childhood.12 EBV  epidemiol-
ogy  in  Argentina  reﬂects  a  typical  pattern  of  a  developing
country  with  primary  infection  in  early  childhood  and  the
epidemiology  of  EBV-related  lymphomas  differs  from  that
observed  in  developing  countries.  Therefore,  EBV  infection
in  our  pediatric  patients  shows  a  complex  epidemiological
pattern,  very  attractive  to  investigate.
3. EBV in pediatric Hodgkin lymphoma
In  the  United  States  and  most  European  countries,  HL  shows
an  annual  incidence  of  4.5-6.0  per  million  and  its  inci-
dence  increases  with  age  and  peaks  between  15  and  30
years.  In  contrast,  in  developing  countries,  it  shows  a  high
incidence  in  children  exceeding  7  per  million  per  annum
and  70%  of  cases  occur  in  children  <  10  years  of  age.15
EBV  presence  in  HL  varies  with  geographic  location,  age,
sex,  clinical  stage,  and  histologic  type.  EBV  is  detected
in  Hodgkin  Reed-Sternberg  (HRS)  cells  in  ∼40%  of  classical
HL  in  the  Western  world,  mostly  in  cases  of  mixed  cel-
lularity  (MC)  and  lymphocyte-depleted  subtypes,  and  less
frequently  in  nodular  sclerosis  and  lymphocyte-rich  classical
subtypes.  EBV  is  rarely  found  in  nodular  lymphocyte  predom-
inant  HL  (NLPHL).16 Developing  countries  have  an  increased
incidence  of  EBV-positive  cases,  which  may  be  attributed  to
the  existence  of  underlying  immunosuppression.17 In  addi-
tion,  in  developed  populations  EBV-positive  HL  also  affects
more  Asians  and  Hispanics  than  whites  or  blacks  and  in  the
UK  is  more  common  in  South  Asian  children  compared  with
non-South  Asian  children.15
Childhood  HL  is  deﬁned  as  affecting  those  patients
≤16  years  of  age.  It  represents  ∼10%  of  all  diagnosed  HL
and  typically  shows  a  signiﬁcant  prevalence  of  male  gender
and  MC  subtype  (30-35%)  in  comparison  with  HL  in  ado-
lescent/young  adults  or  adults.  Like  its  adult  counterpart,
∼40-50%  of  HL  cases  are  associated  with  EBV  in  devel-
oped  countries.18 HL  is  more  likely  to  be  EBV-associated  to
boys  <  10  years  of  age  than  to  young  adults.  This  led  to
the  suggestion  that  HL  consists  of  three  disease  entities:
pediatric  HL  (EBV-positive,  mixed  cellularity  type),  HL  of
young  adults  (EBV-negative,  nodular  sclerosis  type),  and  HL
of  older  adults  (EBV-positive,  mixed  cellularity  type).15
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In  Argentina,  our  group  previously  reported  an  epidemi-
logical  pattern  II  together  with  an  EBV  association  of  31%
or  adult  HL,  which  rose  up  to  54%  in  pediatric  patients.19--21
n  pediatric  HL  in  Central  and  South  America,  several
roups  demonstrated  an  EBV-association  that  could  be  up
o  90%.16 Therefore,  EBV  presence  in  childhood  HL  from
ur  series  resembles  the  scenario  observed  in  developed
ountries.  In  spite  of  this,  EBV  was  statistically  associ-
ted  with  MC  subtype  and  males  (p  <  0.05,  2 test),  typical
f  an  underdeveloped  or  developing  population.  In  addi-
ion,  when  only  children  <  10  years  of  age  were  analyzed,
hey  displayed  distinctive  characteristics.  EBV  was  statis-
ically  distributed  in  74%  of  patients  <  10  years  of  age
s.  34%  observed  in  patients  11-16  years  (p  <  0.0001,  2
est).  Furthermore,  EBV+  cases  had  a median  age  of  8
ears  vs.  a  median  of  12  years  observed  in  EBV-  cases
p  =  0.006,  Mann-Whitney  test)  (authors’  unpublished  data).
hese  paradoxical  epidemiological  characteristics  make  our
opulation  a quite  interesting  group  for  analysis.  In  con-
rast,  in  southeast  Brazil,  where  both  EBV  primary  infection
nd  EBV-associated  pediatric  HL  reveal  the  same  pattern
s  in  Argentina,  EBV+  HL  was  not  signiﬁcantly  distributed
n  patients  <  10  years  of  age  or  MC  subtype.22,23 However,
hildhood  HL  from  northeast  Brazil  display  87%  of  EBV+  cases
ogether  with  a  prevalence  of  MC  subtype,24 as  in  underde-
eloped  populations.  In  line  with  this,  Mexico  and  Peru  also
howed  a  high  frequency  of  EBV-associated  HL,  70%  and  94%,
espectively.25,26
EBV-associated  tumors  display  three  classical  patterns
ith  differential  expression  of  latency  proteins,  in  part
s  a  consequence  of  host  immune  response  to  EBV  anti-
ens.  Latency  III  expresses  EBNA1,  -2,  -3A,  -3B,  -3C,  -LP
ogether  with  LMP1  and  -2  and  the  non-coding  RNAs  (EBERs,
icroRNAs,  and  BARTs),  typically  associated  with  post-
ransplant  lymphoproliferative  disorders.  All  other  latency
ypes  involve  increasing  degrees  of  viral  gene  silencing.  In
atency  I,  observed  in  BL,  only  EBNA1  and  the  non-coding
NAs  are  expressed,  whereas  EBNA1,  LMP1  and  -2  and  the
on-coding  RNAs  are  expressed  in  the  latency  II program,
elated  to  HL.27 It  was  proposed  that  LMP1  rescue  pro-
poptotic  germinal  center  B-cells  with  crippling  mutations
n  the  heavy  chain  immunoglobulin  locus  from  apoptosis,28
hereas  LMP2A  may  act  as  an  indispensable  BCR-mimic  in
CR-positive  and  BCR-negative  germinal  center  B-cells,29
ointing  to  its  crucial  role  in  the  rescue  of  these  cells
rom  apoptosis  and  in  the  HL  transformation  process  as
ell.  On  the  other  hand,  Thorley-Lawson  et  al.  suggested
 modest  signaling  role  for  LMP1  and  LMP2A  in  GC  B-cells,
ased  on  the  presence  of  high  afﬁnity  antibodies  in  LMP1
nd  LMP2A  positive  germinal  center  B-cells.30 In  Argentina,
e  found  latency  II  pattern  in  our  HL  series,  deﬁned  by
MP1  expression  in  cytoplasm  membrane  of  HRS  cells.  Given
hat  HRS  cells  derive  from  crippled,  pre-apoptotic  germi-
al  center  B-cells,16 LMP1  expression  in  our  cases  could  be
esponsible  for  rescuing  those  cells  from  apoptotic  stimuli.
n  a  preliminary  study  of  LMP1  expression  in  tonsils  from
ediatric  EBV+  patients,  we  found  that  LMP1+  cells  were
revalent  outside  the  germinal  centers  (authors’  unpub-
ished  data).  This  fact  could  imply  that  LMP1  presence  in
nly  a  small  number  of  cases  might  prevent  apoptosis  and
ead  to  ﬁrst  steps  in  malignant  transformation  towards  HRS
ells.
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The  risk  of  HL  after  IM  suggests  that  the  predilection  for
he  younger  adult  age  group  may  simply  result  from  the  com-
ination  of  age  and  time  since  IM.  Therefore,  given  the  fact
hat  in  Argentina  primary  infection  occurs  at  early  age  and
s  mostly  subclinical,  and  HL  prevail  in  patients  <  10  years
ld,  a  similar  association  may  exist  between  primary  EBV
nfection  and  HL  risk  in  childhood.
. EBV in pediatric Burkitt lymphoma
urkitt  lymphoma  (BL)  can  be  classiﬁed  into  three  forms,
hich  differ  in  geographic  distribution  and  EBV  association:
ndemic  (eBL),  sporadic  (sBL)  and  HIV-associated  BL.31 The
igh-incidence  ‘‘endemic’’  form  typically  presents  as  a  jaw
r  abdominal  tumor  in  children  in  areas  of  equatorial  Africa
nd  Papua  New  Guinea  where  malaria  is  holoendemic  and  is
lmost  100%  EBV+.  Elsewhere,  BL  occurs  in  ‘‘sporadic’’  form,
gain  mainly  in  children,  at  intermediate  to  low  incidence
nd  with  different  degrees  of  EBV  association  depending
pon  the  area.  Western  countries  show  the  lowest  inci-
ence  rates  and  the  weakest  virus  association,  with  only
5%  to  20%  tumors  being  EBV+.  Remarkably,  a  third,  adult
orm  of  the  tumor,  AIDS-BL,  proved  to  be  very  common
mong  HIV-infected  individuals,  often  appearing  as  one  of
he  ﬁrst  symptoms  of  AIDS;  30%  to  40%  of  these  tumors  carry
BV.32 The  hallmark  of  all  BL  tumors  is  the  translocation
etween  the  MYC  gene  and  one  of  the  immunoglobulin  (Ig)
eavy  or  light  chain  loci.31 BL  cells  phenotypically  resem-
le  centroblasts.  Moreover,  many  BL  cells  and  also  some
L-derived  cell  lines  show  evidence  of  active  somatic  hyper-
utation,  a  further  hallmark  of  germinal-center  B  cells.  The
tructure  of  the  chromosome  breakpoints  derived  from  the
nalysis  of  MYC-Ig  translocations  strongly  indicates  that  the
ranslocations  occurred  either  as  a  mistake  of  class  switch
ecombination  or  somatic  hypermutation,  both  processes
hat  occur  in  germinal-center  B  cells.33 There  is  some  evi-
ence  that  the  original  cell  may  derive  from  a  post-GC  or
emory  B  cell  re-entering  the  GC  and  may  differ  in  EBV-
ositive  and  -negative  tumors;  however,  it  is  clear  that
erminal  center  involvement  is  critical  for  the  pathogene-
is  of  this  disease  both  in  terms  of  MYC  translocation  events
nd  the  contribution  of  co-factors  such  as  EBV,  malaria  or
IV  infection.31
In  Argentina,  our  group  demonstrated  an  EBV  association
ith  pediatric  BL  in  37%  of  cases,  including  immunocom-
etent  and  immunocompromised  patients.  All  HIV+  patients
100%)  were  EBV+,  whereas  29%  of  the  immunocompetent
atients  displayed  EBV  presence  in  tumor  cells.  EBV  pres-
nce  in  BL  biopsies  was  analyzed  according  to  age,  and  the
irus  was  statistically  distributed  in  patients  <  5  years  old
p  < 0.0001,  2 test).  Furthermore,  as  also  demonstrated  for
BV-associated  HL,  the  median  age  of  EBV-positive  patients
as  lower  (3  years  old)  than  that  observed  for  EBV  nega-
ive  ones  (8  years  old)  (p  =  0.0027,  Mann--Whitney  test).34
emarkably,  a  sporadic  EBV  association  with  BL  (29%)  in
mmunocompetent  patients  was  observed  in  our  series.
n  contrast,  variable  regionally  EBV  association  with  BL  was
escribed  in  Brazil,  varying  from  29%  in  the  South  to  76%  in
he  North,  but  higher  in  pediatric  groups  from  all  regions.35
he  scenario  for  BL  in  HIV-infected  patients  was  quite  dif-
erent  from  that  described  previously  because  these  series
e
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howed  an  interesting  100%  EBV  association  with  pediatric
L  patients  infected  with  HIV,  higher  than  the  typical  30-40%
eported  for  this  entity.32
Latency  I  pattern  seen  in  most  endemic  BL  tumors  is
haracterized  by  the  restricted  expression  of  a  single  latent
ntigen  EBNA1  transcribed  from  Qp  viral  promoter,  differ-
nt  from  the  latency  III  EBNA  transcripts,  which  are  driven
y  either  of  two  promoters,  Cp  or  Wp.  However,  another
ype  of  latency,  termed  Wp-restricted  latency,  character-
zed  by  expression  of  EBNA1,  EBNA3A,  EBNA3B,  EBNA3C,
BNA-LP  and  BHRF1in  the  absence  of  EBNA2  and  the  LMPs,
as  also  demonstrated  in  a  subset  of  endemic  BL  tumors  that
arry  EBV  genomes  deleted  for  the  EBNA2  gene.33 For  that
eason,  we  studied  viral  latency  proﬁles  by  LMP1  immuno-
istochemistry  and  RT-PCR.  Most  EBV+  cases  (80%)  displayed
he  typical  latency  I  proﬁle  described  in  BL,  whereas
he  remaining  20%  showed  also  LMP1  immunohistochemi-
al  expression,  remarkably  those  cases  were  HIV-infected
atients.  This  pattern  did  not  match  either  with  latency  I
r  Wp-restricted  pattern  described  for  Burkitt  lymphoma  or
ith  latency  III  pattern  associated  with  EBV-positive  lym-
homas  in  immunosuppressed  patients.  In  addition,  LMP2A
atent  gene  as  well  as  BZLF1  and  BHRF1  lytic  genes  were  not
etected  by  RT-PCR,  whereas  EBNA1  transcripts  driven  from
p  promoters  were  demonstrated  in  the  absence  of  Wp/Cp
romoter  usage.34 Only  one  group  has  previously  reported
MP1  expression  without  LMP2A  by  RT-PCR  in  2  eBL  patients
rom  Africa.36 It  can  be  hypothesized  that  LMP1  expression
n  BL  patients  infected  with  HIV  could  arise  from  a  germinal
enter  cell  that  failed  to  turn-off  selectively  LMP1  expres-
ion  to  achieve  the  full  BL  latency  I  phenotype,  promoted  by
IV  presence.  Alternatively,  the  presence  of  HIV-associated
mmunosuppression  allows  the  unchecked  proliferation  of
BV-infected  lymphocytes  expressing  latent  antigens  differ-
nt  from  typical  latency  I.34
. EBV in pediatric diffuse large B-cell
ymphoma
orldwide,  diffuse  large  B-cell  lymphoma  (DLBCL)  rep-
esents  the  most  common  subtype  of  NHL,  accounting
or  30%  to  40%  of  all  newly  diagnosed  cases.  Two  dis-
inct  subtypes  have  been  identiﬁed,  termed  germinal
enter  cell  and  post-germinal  center,  which  are  believed
o  represent  lymphomas  arising  from  different  stages  of
ymphoid  differentiation.37 The  2008  World  Health  Organi-
ation  (WHO)  classiﬁcation  of  tumors  of  hematopoietic  and
ymphoid  tissues  has  recognized  a  new  provisional  entity
esignated  as  EBV-positive  DLBCL  of  the  elderly.  It  has
een  postulated  that  EBV-positive  DLBCL  of  the  elderly
ight  be  caused  by  the  senescence  of  the  immune  sys-
em  as  a  part  of  the  normal  aging  process,  based  largely
n  shared  features  with  immunodeﬁciency-LPDs.38 The  age
utoff  for  EBV-positive  DLBCL  was  set  as  >  50  years.  How-
ver,  recent  reports  show  that  EBV-positive  DLBCL  can
ffect  younger  patients,39 including  our  study.40 Further-
ore,  in  some  previous  reports,  patients  <  50  years  old  were
ven  excluded  from  the  studies.39 Therefore,  it  is  not  evi-
ent  that  EBV-positive  DLBCL  in  young  adults  has  distinct
linical  features  and  outcome  compared  to  their  elderly
ounterpart.
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Table  1  Comparison  between  EBV  positive  and  negative  pediatric  lymphomas  between  developed  countries  and  Argentina.
Pediatric Hodgkin lymphoma Pediatric Burkitt lymphoma Pediatric diffuse large B-cell lymphoma
Developed
countries
Argentina Developed
countries
Argentina Developed
countries
Argentina
Annual incidence/million 4.5-6.0 6.94 Annual incidence/million Uncertain 2.93 Annual incidence/million Uncertain Uncertain
Peak age at presentation
EBV+
Adolescent/young
adult
8  years Peak age at presentation
EBV+
Adolescent/young
adult
3  years Peak age at presentation
EBV+
Adolescent/young
adult
6  years
Peak age at presentation
EBV-
Adolescent/young
adult
12  years Peak age at presentation
EBV-
Adolescent/young
adult
11  years Peak age at presentation
EBV-
Adolescent/young
adult
11  years
% of EBV+ ≥10 y group Uncertain 34% % of EBV+ ≥10 y group Uncertain 34% % of EBV+ ≥10 y group Uncertain 10%
% of EBV+ ≤10 y group Uncertain 74% % of EBV+ ≤10 y group Uncertain 80% % of EBV+ ≤10 y group Uncertain 60%
Overall % of EBV+
pediatric HL
40-50% 54% % of EBV positive sBL 15-20% 29% % of EBV-positive IC
DLBCL
Uncertain 26%
Latency type Classic latency II Classic
latency II
%  of EBV positive HIVaBL 30-40% 100% % of EBV positive
HIVaDLBCL
Uncertain 100%
% of EBV positive in all BL Uncertain 37% % of EBV positive in all
DLBCL
Uncertain 40%
Latency type Classic latency I 80% latency 1
20% latency I + LMP1
Latency type Uncertain Latency III > II  with
some lytic replication
sBL, sporadic Burkitt lymphoma; HIVaBL, HIV-associated Burkitt lymphoma; IC DLBCL, immunocompetent diffuse large B-cell lymphoma; HIVaDLBC, HIV-associated diffuse large B-cell lymphoma.
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DLBCL  is  rarely  diagnosed  in  children  <  4  years  of  age,
ut  the  proportion  of  patients  with  DLBCL  increases  through-
ut  childhood  toward  the  second  decade  of  life.41 The  role
f  EBV  in  pediatric  DLBCL  pathogenesis  remains  uncertain;
herefore,  we  assessed  EBV  association  as  well  as  viral  gene
xpression  in  the  DLBCL  pediatric  population  from  our  hos-
ital.  EBV  association  with  DLBCL  rose  up  to  40%,  using  20%
f  EBERs+  cells  as  cut-off  value;  nevertheless,  when  exclud-
ng  immunosuppressed  patients,  this  association  decreased
o  26%.42 There  are  only  few  studies  dealing  with  EBV  pres-
nce  in  DLBCL.  Our  overall  percentage  was  very  similar  to
hose  observed  in  previous  reports  restricted  to  African  chil-
ren,  which  analyzed  series  of  NHL  that  included  a  subset  of
LBCL  and  described  an  association  of  43-44%  between  EBV
nd  this  lymphoma  subtype,  even  though  the  immunolog-
cal  status  of  these  patients  was  not  clearly  speciﬁed.43,44
BV  presence  in  pediatric  DLBCL  patients  was  sorted  in
wo  age  groups:  less  than  10  years  (≤10  years)  and  11--16
ears  (>10  years).  The  number  of  EBV+  cases  was  sig-
iﬁcantly  higher  among  patients  ≤  10  years  than  among
atients  >  10  years (p  <  0.018,  Fisher’s  exact  test).  Moreover,
edian  age  of  EBV-positive  patients  was  6  years  vs.  11  years
bserved  in  the  negative  patients  (p  =  0.005,  Mann  Whitney
est).  This  observation  together  with  the  high  association
n  childhood  HL  as  well  as  BL  conﬁrms  that  EBV  could  be
n  important  cofactor  in  B-cell  lymphomagenesis  in  younger
hildren  in  Argentina.42
Previous  studies  suggested  that  EBV+  DLBCL  in  elderly
atients  generally  showed  a  viral  latency  type  II  or  III
attern,45,46 whereas  viral  latency  pattern  was  not  pre-
iously  described  in  pediatric  and  young  adults  patients.
n  our  pediatric  DLBCL  series,  latency  pattern  III  was  the
ost  frequently  observed  together  with  lytic  gene  expres-
ion,  followed  by  latency  II  pattern.42 BZLF1  lytic  gene
xpression  could  mirror  a  percentage  of  cells  undergoing
ytic  phase,  as  previously  observed  for  BL.47 A  mixture  of
atency  II  or  III  and  a  lytic  EBV  gene  was  also  observed
n  our  adult  lymphoma  series  from  Argentina,  in  both
atients  younger  and  older  than  50  years.40 This  ﬁnding
uggests  that  the  entity  EBV+  DLBCL  of  the  elderly  can
ccur  in  pediatric  and  young  immunocompetent  patients
nd  might  not  be  an  age  related-EBV  association.  In  addi-
ion,  latency  III  pattern  together  with  lytic  viral  antigen
xpression  in  DLBCL  from  Argentina  suggest  that  lytic  cycle
ay  play  an  unexpected  role  in  virus-mediated  oncogene-
is.
In  order  to  reinforce  the  hypothesis  of  EBV-association
ot  exclusively  related  to  elderly  patients,  DLBCL  microen-
ironment  was  studied  in  pediatric,  younger  and  older  than
0  years  old  patients.  CD3,  CD8,  CD4  and  Foxp3  positive
ells  were  compared  in  those  three  groups  and  in  rela-
ion  to  EBV  presence.  Remarkably,  we  did  not  observe
ajor  differences  linked  with  age  of  the  relative  numbers
f  any  T-cell  population  analyzed.40,42 This  fact,  together
ith  EBV  association  with  both  age  groups,  might  con-
rm  previous  statements  that  the  deﬁnitional  cutoff  of  50
ears  proposed  by  the  WHO  could  be  arbitrary48 because
ases  <  50  years  of  age  can  be  found  and  suggest  that,  at
east  for  T-cell  populations  analyzed,  immunosenescence
ould  be  ruled  out.  Concerning  EBV  status,  no  signiﬁ-
ant  difference  was  found  among  each  cellular  marker
nvestigated.40,42P.  Chabay,  M.V.  Preciado
. Concluding remarks and future
erspectives
rom  the  ﬁrst  discovery  of  EBV  particles  in  sub-Saharan
L,  the  virus  has  now  been  found  in  many  more  tumors  of
,  T,  NK  and  epithelial  cell  origin.  Overall,  EBV  seems  to
ontribute  to  ∼2%  of  all  tumor  burdens  in  man.  Therefore,
he  question  that  drives  most  research  into  EBV  since  its
iscovery  is  why  some  individuals  develop  EBV-associated
umors,  whereas  most  control  the  virus  without  symptoms.49
n  fact,  it  remains  to  be  elucidated  whether  EBV-association
ith  lymphoma  reﬂects  causality.  The  increased  risk  of
L  development  a  few  years  after  IM  leads  to  speculate
hat  a  similar  association  may  exist  between  primary  EBV
nfection  and  HL  risk  at  any  age,  for  example,  in  childhood.
 higher  prevalence  of  EBV  in  lymphomas  diagnosed  in
hildren  <  10  years  old  was  demonstrated  by  our  research
roup  not  only  in  pediatric  HL,20,21 but  also  in  BL34 and
LBCL.42 Therefore,  in  our  country,  EBV  infection  shows
nteresting  epidemiological  characteristics  to  study  viral
athogenesis.  Given  that  in  Argentina  children  are  infected
uite  early  in  their  life  and  nearly  70%  of  children  are
eropositive  by  the  age  of  2  years,10 we  hypothesize
hat  infection  with  EBV  early  in  life  increases  the  risk
f  developing  EBV-associated  lymphoma  and  may  be  as
 late  complication  of  primary  infection.  A  comparison
f  EBV-positive  pediatric  lymphomas  between  developed
ountries  and  our  own  data  from  Argentina  is  presented  in
able  1. It  is  well  accepted  that  IM  often  precedes  HL  and
hat  IM  is  an  adolescent/young  adult  disease,  but  to  our
nowledge  there  is  not  a  clear  consensus  of  the  median  age
f  presentation  in  developed  countries.  Still  more  confusing
s  the  literature  about  BL  and  DLBCL  because  most  studies
o  not  distinguish  between  EBV-positive  and  -negative
ases  and  because  of  the  multiple  presentation  forms;  for
nstance,  BL  sporadic,  endemic  or  HIV  associated  and  DLBCL
f  immunocompetent  or  immunosuppressed  patients.
Our  preliminary  results  in  tonsils  from  pediatric  carri-
rs  show  that  a  latency  III  pattern  prevails  and,  based  on
he  known  oncogenic  potential  of  EBV  in  vitro, we  can  pro-
ose  that  the  synergism  of  oncogenic  viral  proteins  could
ccur  in  these  cases  (personal  observations).  This  ﬁnding
uggests  that  there  could  be  an  implication  of  EBV  infection
nvolved  in  B-cell  lymphoma  development  in  our  country,
nd  emphasizes  the  need  for  epidemiological  studies  involv-
ng  different  centers  from  the  Latin  American  region  to
onﬁrm  this  hypothesis.
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